Hydroxychloroquine Administration for Reduction of Pexophagy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
A series of N-of-1, crossover, randomized, placebo-controlled, double-blinded trial. Hydroxychloroquine (HCQ) and a crossover to placebo (order is randomized and blinded) will be administered in liquid suspension for 84 days (12 weeks) each with an 84 day washout in between. We hypothesize that HCQ will reduce peroxisomal turnover, which will arrest ongoing injury in PBDs caused by PEX1, PEX6 or PEX26.
Epistemonikos ID: fadad28fc61c8f66f70daa9255031d7c63bf5db1
First added on: May 22, 2024